Sun Pharmaceutical Industries Ltd
Acquisition of Innovcare Lifesciences Private Limited
M&A
▲ Positive Development
LOW RISK
📅 Filed on BSE: 20 Jun 2026, 05:23 PM IST · BSE ID: f4f80d88-e5fb-41cb-b0e0-006e84a0edc3
View Original BSE Filing (PDF)
💡
In Simple Terms
Sun Pharma bought Innovcare Lifesciences, a company selling medicines and health products, for ~Rs 271.2 Crores.
🤖 AI Summary
- Sun Pharma acquired 100% of Innovcare Lifesciences Private Limited for ~Rs 271.2 Crores.
- Innovcare Lifesciences reported revenue from operations of INR 94.06 crores for FY 2025-26.
- The acquisition is a strategic investment to strengthen Sun Pharma's product portfolio.
- The transaction is a cash consideration, expected to complete on or before 31 July 2026.
- No governmental or regulatory approvals are required for this acquisition.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Acquisition Cost
~Rs 271.2 Crores
Innovcare Revenue FY 2025-26
INR 94.06 crores
Innovcare Revenue FY 2024-25
INR 86.09 crores
Innovcare Revenue FY 2023-24
INR 80.93 crores
Percentage of Shareholding Acquired
100%
🏢 How This Affects the Company
This acquisition expands Sun Pharma's product portfolio across pharmaceutical, nutraceutical, and cosmeceutical segments, integrating Innovcare's existing marketing and distribution network.
Sun Pharma will disburse a cash consideration of ~Rs 271.2 Crores for the acquisition, impacting its cash reserves and potentially contributing to future revenue streams from Innovcare's operations.
The acquisition integrates Innovcare's business of marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products into Sun Pharma's existing operations.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders as this is an acquisition disclosure.
👤
Who Is Affected
Existing shareholders of Sun Pharmaceutical Industries Ltd will see their company's business expand through the acquisition of Innovcare Lifesciences Private Limited, which had FY 2025-26 revenue of INR 94.06 crores.
🔍
Management Signal
This decision reveals management's intent to strengthen and diversify the product portfolio through strategic acquisitions using cash consideration.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Sun Pharma's Q1 FY27 results — monitor financial impact of Innovcare acquisition.
Official announcement of acquisition completion by 31 July 2026.
Future investor presentations for synergy details of Innovcare integration.
LOW RISK
The acquisition is for 100% shares via cash, with no regulatory approvals required, limiting completion risk.
💡 Investor Takeaway
Sun Pharmaceutical Industries Ltd acquired Innovcare Lifesciences Private Limited for ~Rs 271.2 Crores, securing 100% outstanding shares. Innovcare reported INR 94.06 crores in revenue for FY 2025-26, reflecting a 9.26% YoY growth. The acquisition aims to strengthen the company's product portfolio and is expected to complete by 31 July 2026.
⚖️ Strengths & Concerns
✅ Positives
- Innovcare Lifesciences recorded a revenue from operations of INR 94.06 crores in FY 2025-26, showing 9.26% growth from FY 2024-25.
- The acquisition requires no governmental or regulatory approvals, indicating a streamlined and efficient completion process.
⚠️ Concerns
- The acquisition cost of ~Rs 271.2 Crores represents a multiple of approximately 2.88 times Innovcare's FY 2025-26 revenue of INR 94.06 crores.
- Innovcare's revenue growth has slowed, from 6.37% in FY 2024-25 (INR 80.93 crores to INR 86.09 crores) to 9.26% in FY 2025-26 (INR 86.09 crores to INR 94.06 crores).
📅 Company Track Record
This acquisition follows Sun Pharma's definitive agreement to acquire Organon, announced on 26 April 2026, for which deal details and valuation are pending disclosure. The current Innovcare acquisition represents a separate, completed agreement.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What is the acquisition cost for Innovcare Lifesciences Private Limited by Sun Pharma?
Sun Pharmaceutical Industries Limited agreed to acquire Innovcare Lifesciences Private Limited for a cash consideration aggregating ~Rs 271.2 Crores.
What was Innovcare Lifesciences Private Limited's revenue for FY 2025-26?
Innovcare Lifesciences Private Limited reported a revenue from operations of INR 94.06 crores for FY 2025-26.
What percentage of Innovcare Lifesciences Private Limited is Sun Pharma acquiring?
Sun Pharmaceutical Industries Limited has agreed to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited.
What is the primary business of Innovcare Lifesciences Private Limited?
Innovcare Lifesciences Private Limited is engaged in the business of marketing, distribution, and sale of pharmaceutical drugs, nutraceutical, and cosmeceutical products.
By when is the acquisition of Innovcare Lifesciences Private Limited expected to be completed?
The acquisition of Innovcare Lifesciences Private Limited is expected to be completed on or before 31 July 2026.
Questions based on this BSE filing only. For information purposes.